IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis - 01/10/15
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and objective |
The IL-28B rs12979860 CC and rs8099917 TT genotypes were proved to be predictor for pegylated-interferon (PEG-IFN)/ribavirin (RBV)-treated hepatitis C virus (HCV) patients. However, there were no identical conclusions on rs12980275 polymorphism. Our aim is to perform a meta-analysis in order to determine the association between rs12980275 polymorphism of IL28B and the sustain viral response (SVR) of HCV patients with PEG-IFN/RBV therapy.
Methods |
Studies were retrieved from PubMed and Chinese China National Knowledge Infrastructure (CNKI). Data were extracted by two investigators and analyzed using Stata 11.0 software.
Results |
Sixteen articles, containing 19 independent studies were included in the analysis. The results showed that patients with AA genotype of rs12980275 achieved higher SVR than patients with AG/GG genotypes. The overall OR (95% CI) was 3.118 (2.146, 4.529). In subgroup analysis by ethnicity, the ORs (95% CIs) were 3.084 (1.454, 6.542) and 2.736 (1.863, 4.018) in Asian and Caucasian population, respectively. Another subgroup analysis by HCV genotype, the ORs (95% CIs) were 3.976 (2.568, 6.158), 1.462 (0.504, 4.240) and 1.489 (0.916, 2.421) in patients with HCV genotype 1/4, mix genotype, and HCV genotype 2/3, respectively.
Conclusion |
AA genotype of rs12980275 was a predictive factor for SVR in HCV patients with PEG-IFN/RBV treatment, especially in HCV genotype 1/4.
Le texte complet de cet article est disponible en PDF.Plan
Vol 39 - N° 5
P. 576-583 - octobre 2015 Retour au numéro
Article précédent
- Portable hemoglobinometer is a reliable technology for the follow-up of venesections tolerance in hemochromatosis
- Maxime Pawlowski, Fanny Latute, Edouard Bardou-Jacquet, Marianne Latournerie, Selim Zerrouki, Claude Bendavid, Pierre Brissot, Martine Ropert
- A meta-analysis of single-stage versus two-stage management for concomitant gallstones and common bile duct stones
- Hong-Yi Zhu, Ming Xu, Huo-Jian Shen, Chao Yang, Fu Li, Ke-wei Li, Wei-Jin Shi, Fu Ji
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?